Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics

Lilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.

Continue reading →